Total Payments
$49,582
2024 Payments
$4,443
Companies
7
Transactions
64
Medicare Patients
617
Medicare Billing
$112,570
Payment Breakdown by Category
Research$34,077 (68.7%)
Other$12,500 (25.2%)
Travel$1,623 (3.3%)
Food & Beverage$1,089 (2.2%)
Education$293.21 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $34,077 | 26 | 68.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,500 | 7 | 25.2% |
| Travel and Lodging | $1,623 | 6 | 3.3% |
| Food and Beverage | $1,089 | 19 | 2.2% |
| Education | $293.21 | 6 | 0.6% |
Payments by Type
Research
$34,077
26 transactions
General
$15,506
38 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $32,737 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $13,136 | 17 | $0 (2018) |
| Merck Sharp & Dohme LLC | $1,820 | 9 | $0 (2023) |
| ABBVIE INC. | $1,340 | 11 | $0 (2024) |
| Novo Nordisk Inc | $274.07 | 7 | $0 (2021) |
| Abbott Laboratories | $212.56 | 3 | $0 (2024) |
| Nevro Corp. | $63.46 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,443 | 16 | Eli Lilly and Company ($3,077) |
| 2023 | $10,980 | 17 | Eli Lilly and Company ($9,160) |
| 2022 | $20,500 | 4 | Eli Lilly and Company ($20,500) |
| 2021 | $110.39 | 3 | Novo Nordisk Inc ($64.54) |
| 2018 | $3,965 | 7 | AstraZeneca Pharmaceuticals LP ($3,897) |
| 2017 | $9,584 | 17 | AstraZeneca Pharmaceuticals LP ($9,239) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: DIABETES CARE | ||||||
| 10/07/2024 | Eli Lilly and Company | — | — | In-kind items and services | $947.54 | Research |
| Study: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,160.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $969.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | ||||||
| 08/06/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $11.78 | General |
| Category: DIABETES CARE | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $420.80 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $69.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $125.05 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $70.25 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 09/11/2023 | Eli Lilly and Company | — | — | In-kind items and services | $535.01 | Research |
| Study: A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | ||||||
| 07/13/2023 | Eli Lilly and Company | — | — | In-kind items and services | $665.01 | Research |
| Study: A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | ||||||
| 06/16/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $917.02 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $254.90 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $56.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/14/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $254.90 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | Eli Lilly and Company | $10,525 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $9,975 | 2 |
| A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $4,400 | 1 |
| A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $2,198 | 1 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,340 | 11 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $1,160 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $969.00 | 1 |
| A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITHOUT TYPE 2 DIABETES | Eli Lilly and Company | $947.54 | 1 |
| A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $795.01 | 1 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $665.01 | 1 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $535.01 | 1 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | Eli Lilly and Company | $227.94 | 1 |
| A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | Eli Lilly and Company | $221.40 | 1 |
| RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $118.56 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 123 | 167 | $53,508 | $16,242 |
| 2021 | 5 | 253 | 533 | $168,390 | $56,736 |
| 2020 | 4 | 241 | 450 | $134,652 | $39,591 |
Total Patients
617
Total Services
1,150
Medicare Billing
$112,570
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 91 | 104 | $43,680 | $13,600 | 31.1% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2022 | 32 | 63 | $9,828 | $2,642 | 26.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 131 | 293 | $123,060 | $42,532 | 34.6% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2021 | 65 | 172 | $26,832 | $8,094 | 30.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 32 | $9,984 | $3,438 | 34.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 16 | 21 | $6,279 | $1,855 | 29.5% |
| 95249 | Continuous monitoring of glucose in tissue fluid using sensor under skin | Office | 2021 | 14 | 15 | $2,235 | $817.60 | 36.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 120 | 223 | $89,200 | $26,731 | 30.0% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2020 | 66 | 154 | $23,946 | $7,141 | 29.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 27 | 41 | $12,002 | $3,713 | 30.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 28 | 32 | $9,504 | $2,007 | 21.1% |
About Dr. Frances Broyles, MD
Dr. Frances Broyles, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1669454583.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frances Broyles, MD has received a total of $49,582 in payments from pharmaceutical and medical device companies, with $4,443 received in 2024. These payments were reported across 64 transactions from 7 companies. The most common payment nature is "" ($34,077).
As a Medicare-enrolled provider, Broyles has provided services to 617 Medicare beneficiaries, totaling 1,150 services with total Medicare billing of $112,570. Data is available for 3 years (2020–2022), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Seattle, WA
- Active Since 11/16/2005
- Last Updated 06/20/2008
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1669454583
Products in Payments
- FARXIGA (Drug) $11,161
- BYDUREON (Drug) $1,975
- ARMOUR THYROID (Drug) $1,340
- FreeStyle Lite system (Device) $186.40
- Saxenda (Drug) $108.51
- Ozempic (Drug) $68.75
- Omnia (Device) $45.85
- Tresiba (Drug) $32.27
- FREESTYLE LIBRE 3 (Device) $26.16
- Senza Spinal Cord Stimulation System (Device) $17.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Seattle
Irl Hirsch
Endocrinology, Diabetes & Metabolism — Payments: $227,394
Endocrinology, Diabetes & Metabolism $227,394
Dr. Kristina Utzschneider, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $183,420
Endocrinology, Diabetes & Metabolism $183,420
Dr. Nicole Ehrhardt, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $103,169
Endocrinology, Diabetes & Metabolism $103,169
Michael Schwartz
Endocrinology, Diabetes & Metabolism — Payments: $26,911
Endocrinology, Diabetes & Metabolism $26,911
Alan Chait
Endocrinology, Diabetes & Metabolism — Payments: $21,441
Endocrinology, Diabetes & Metabolism $21,441
Jose Garcia, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $18,810
Endocrinology, Diabetes & Metabolism $18,810